BridgeMD
CARESS Study: Cabergoline for the Reduction of Endometriosis Symptoms and Lesion Size
EU CTIS ID: 2025-522812-18-00
What this study is testing
To evaluate the efficacy of cabergoline (0.5 mg twice weekly) in reducing the size of endometriotic lesions and alleviating pelvic pain in women with confirmed endometriosis, compared with a control group receiving standard treatment (dienogest or combined contraceptives) for endometriosis.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Aged between 18 and 40 years old, and premenopausal.
- Confirmed diagnosis of endometriosis by ultrasound/magnetic resonance imaging/laparoscopy.
- Pelvic pain (≥1 month) assessed using a VAS scale ≥3 points.
- No treatment with cabergoline in the three months prior to the start of the study.
- BMI between 18 and 35 kg/m².
- No allergy to the treatments.
You likely can't join if
- Documented allergy to dopamine agonists or previous serious side effects with cabergoline
- Severe uncontrolled comorbidities (ASA> III).
- Active thromboembolic disease.
- Pregnancy or breastfeeding at the start of the study.
- History of heart valve disorders, history of fibrotic disorders, or impaired liver function.
- Breast Cancer
See the full eligibility criteria
- Aged between 18 and 40 years old, and premenopausal.
- Confirmed diagnosis of endometriosis by ultrasound/magnetic resonance imaging/laparoscopy.
- Pelvic pain (≥1 month) assessed using a VAS scale ≥3 points.
- No treatment with cabergoline in the three months prior to the start of the study.
- BMI between 18 and 35 kg/m².
- No allergy to the treatments.
- Consent to participate in the study.
- Ability to speak and understand the message.
- Documented allergy to dopamine agonists or previous serious side effects with cabergoline
- Severe uncontrolled comorbidities (ASA> III).
- Active thromboembolic disease.
- Pregnancy or breastfeeding at the start of the study.
- History of heart valve disorders, history of fibrotic disorders, or impaired liver function.
- Breast Cancer
- Patient unwillingness to participate in the study
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.